DexCom To Present At Canaccord Genuity 33rd Annual Growth Conference

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, President and Chief Operating Officer, will present an update on the company at the Canaccord Genuity 33rd Annual Growth Conference in Boston on Wednesday, August 14, 2013 at 1:00 pm (EDT). The presentation, which will occur live at the InterContinental Boston Hotel, will be concurrently webcast.

The link to the webcast will be available on the DexCom website at www.dexcom.com by navigating to “About,” then “Investor Relations,” and then “Events and Webcasts” and will be archived there for future reference.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.

Cautionary Statement Regarding Forward Looking Statements

DexCom is a medical device company with a limited operating history. Successful commercialization of the company's products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products in commercial quantities at an acceptable cost, possible delays in the company's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the quarter ended March 31, 2013, as filed with the Securities and Exchange Commission on May 1, 2013.

Copyright Business Wire 2010

If you liked this article you might like

Apple Watch Is on Its Way to Becoming a $6 Billion Business, but Is That Really Enough?

DexCom Shares Rise After FDA Approves G5 Mobile App for Android Devices

Apple Watch Appears on Its Way to Becoming a $6 Billion Business

DexCom Stock Surging on Apple Watch Partnership

Markets Down? Get Used to It: Cramer's 'Mad Money' Recap (Wednesday 5/17/17)